Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

Long Buu Huynh, Mercer University College of Pharmacy

Osteoporosis, or “porous bone”, is a bone disease characterized by a loss of bone mass and change in bone structure. There are no symptoms since osteoporosis is a silent condition. Risk factors that can cause osteoporosis are lifestyle choices, certain diseases, medications, and age. [1] Romosozumab is a medication used to help increase bone formation and decrease bone resorption. Alendronate is classified as an antiresorptive agent and used as first-line therapy for osteoporosis. The aim of this study is to investigate the effectiveness of romosozumab followed by alendronate compared with alendronate alone in postmenopausal women with osteoporosis and a previous fracture. [2]

Continue reading


Thyroid Dysfunction and Fracture Risk

Bo Lively, Mercer University College of pharmacy

According to the American Academy of Family Physicians (AAFP), subclinical hyperthyroidism is defined by low or undetectable serum thyroid-stimulating hormone (TSH) levels, with normal free thyroxine (FT4) and normal total/free triiodothyronine levels. Continue reading